Last Posted: Jun 11, 2020
- Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
E Lawitz et al, ancet Gastro Hepato, June 9, 2020 - Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance.
Douglas Mark W et al. Hepatology communications 2020 Jun (6) 904-915 - Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A ).
Smith Donald B et al. The Journal of general virology 2020 May - Early SARS-CoV-2 outbreak detection by sewage-based epidemiology.
Orive Gorka et al. The Science of the total environment 2020 May 732139298 - HBV variants are common in the "immune-tolerant"phase of chronic hepatitis B.
Yuen Lilly et al. Journal of viral hepatitis 2020 May - CDC Recommendations for Hepatitis C Screening Among Adults in the United States
CDC, April 2020 - Cell-free virus-host chimera DNA from Hepatitis B virus integration sites as a circulating biomarker of hepatocellular cancer.
Li Chiao-Ling et al. Hepatology (Baltimore, Md.) 2020 Mar - Clinical application of thiopurine pharmacogenomics in pediatrics.
Pavlovic Sonja et al. Current drug metabolism 2020 Mar - Human genetics of HCV infection phenotypes in the era of direct-acting antivirals.
Nahon Pierre et al. Human genetics 2020 Feb - Transmission of NS5A resistance associated substitutions among men-who-have-sex-with-men recently infected with hepatitis C virus genotype 1a.
Popping Stephanie et al. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 Feb
.png)
No hay comentarios:
Publicar un comentario